Schlensak C, Benk C, Siepe M, Heilmann C, Beyersdorf F
Department of Cardiovascular Surgery, University Hospital Freiburg, Hugstetterstrasse 55, Freiburg, Germany.
Thorac Cardiovasc Surg. 2010 Feb;58 Suppl 2:S198-201. doi: 10.1055/s-0029-1240685. Epub 2010 Jan 25.
Left ventricular mechanical assist device (LVAD) support is well established as a bridge to transplantation and as an alternative to transplantation in patients with end-stage heart failure. There are currently various LVAD systems available based on different types of pump technology. We present the VentrAssist LVAD, a centrifugal pump, and focus on a surgical implantation technique that may help reduce the complications typically associated with VAD surgery.
412 patients underwent VentrAssist LVAD implantation between June 2003 and January 2009 worldwide. The overall rate of success was 81 % (i.e., ongoing, HTX, or recovery). Interestingly hemolysis is greatly reduced with this intracorporeal centrifugal LVAD compared to other VAD systems with other pump designs. Our surgical implantation technique and strategy may contribute to reducing complications.
The VentrAssist is a powerful and effective LVAD; its use can considerably reduce hemolysis. Long-term follow-up is necessary to determine whether the VentrAssist is appropriate as a bridge to transplant as well as feasible for long-term application.
左心室机械辅助装置（LVAD）支持已被公认为是终末期心力衰竭患者移植的桥梁以及移植的替代方案。目前基于不同类型的泵技术有多种LVAD系统可供使用。我们介绍了VentrAssist LVAD，一种离心泵，并着重介绍一种手术植入技术，该技术可能有助于减少通常与VAD手术相关的并发症。
2003年6月至2009年1月期间，全球有412例患者接受了VentrAssist LVAD植入。总体成功率为81%（即持续使用、接受心脏移植或康复）。有趣的是，与其他具有其他泵设计的VAD系统相比，这种体内离心泵LVAD可大大减少溶血。我们的手术植入技术和策略可能有助于减少并发症。
VentrAssist是一种强大且有效的LVAD；其使用可显著减少溶血。需要进行长期随访以确定VentrAssist作为移植桥梁是否合适以及长期应用是否可行。
